{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:09:04Z","timestamp":1791295744719,"version":"4.1.0"},"reference-count":204,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2011,5,10]]},"DOI":"10.1161\/cir.0b013e31820f2f3e","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T02:56:34Z","timestamp":1301367394000},"page":"2022-2060","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":249,"title":["2011 ACCF\/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina\/ Non\u2013ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)"],"prefix":"10.1161","volume":"123","author":[{"name":"2011 Writing Group Members","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Wright","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."},{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Adams","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Bridges","sequence":"additional","affiliation":[{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."},{"name":"Society of Thoracic Surgeons Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Donald E.","family":"Casey","sequence":"additional","affiliation":[{"name":"American College of Physicians Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Ettinger","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Task Force on Practice Guidelines Liaison."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Fesmire","sequence":"additional","affiliation":[{"name":"American College of Emergency Physicians Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore G.","family":"Ganiats","sequence":"additional","affiliation":[{"name":"American Academy of Family Physicians Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."},{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."},{"name":"ACCF\/AHA Task Force on Performance Measures Liaison."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Philippides","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Theroux","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."},{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette K.","family":"Wenger","sequence":"additional","affiliation":[{"name":"ACCF\/AHA Representative."},{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Patrick","family":"Zidar","sequence":"additional","affiliation":[{"name":"Recused from voting on Section 3.2. Recommendations for Antiplatelet\/Anticoagulant Therapy in Patients for Whom Diagnosis of UA\/NSTEMI Is Likely or Definite and Section 5.2.1. Recommendations for Convalescent and Long-Term Antiplatelet Therapy."},{"name":"Society of Coronary Angiography and Interventions Representative."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","unstructured":"ACCF\/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF\/AHA Task Force on Practice Guidelines: Available at: http:\/\/assets.cardiosource.com\/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf Accessed December 20 2010."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.013"},{"key":"e_1_3_2_4_2","first-page":"81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2013 I","volume":"308","author":"Antiplatelet Trialists' Collaboration.","year":"1994","unstructured":"Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy\u2013 I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81\u2013106.","journal-title":"Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511283132201"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.1.81"},{"key":"e_1_3_2_7_2","first-page":"396","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina","volume":"309","author":"Lewis HD","year":"1983","unstructured":"Lewis HD, Davis JW, Archibald DG, et al.. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396\u2013403.","journal-title":"Results of a Veterans Administration Cooperative Study. N Engl J Med"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92336-G"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191701"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361401"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.24.3017"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.010"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.6.591"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07442-1"},{"key":"e_1_3_2_20_2","first-page":"1488","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"PRISM-PLUS Study Investigators.","year":"1998","unstructured":"PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488\u201397.","journal-title":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000046487.06811.5e"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05060-1"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442501"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)07349-3"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.joc60034"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61088-4"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000161383.06692.d4"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.049"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.559088"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.015"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.21.2497"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60450-4"},{"key":"e_1_3_2_36_2","unstructured":"Prasugrel [package insert]. Indianapolis IN: Eli Lilly & Co; 2009. http:\/\/pi.lilly.com\/us\/effient.pdf. Accessed 1\/31\/2011."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.828541"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901316"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807986"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410140100032"},{"key":"e_1_3_2_41_2","first-page":"447","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen M","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447\u201352.","journal-title":"Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.15.1593"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1602"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.042"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.6.1324"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.522805"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(00)02133-0"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020798"},{"key":"e_1_3_2_50_2","first-page":"516","article-title":"Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials","volume":"70","author":"Lincoff AM","year":"2000","unstructured":"Lincoff AM, LeNarz LA, Despotis GJ, et al.. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb\/IIIa blockade Evaluation of Platelet IIb\/IIIa Inhibition in STENTing. Ann Thorac Surg. 2000;70:516\u201326.","journal-title":"Improve Long-term Outcome with abciximab GP IIb\/IIIa blockade Evaluation of Platelet IIb\/IIIa Inhibition in STENTing. Ann Thorac Surg"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.117838"},{"key":"e_1_3_2_52_2","first-page":"866","article-title":"Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT","volume":"70","author":"Dyke CM","year":"2000","unstructured":"Dyke CM, Bhatia D, Lorenz TJ, et al.. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg. 2000;70:866\u201371.","journal-title":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)01366-1"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)00190-5"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000032917.33237.e0"},{"key":"e_1_3_2_56_2","first-page":"1107","article-title":"Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes","volume":"150","author":"Mehta SR","year":"2005","unstructured":"Mehta SR, Yusuf S, Granger CB, et al.. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005;150:1107.","journal-title":"Am Heart J"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055443"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.04.036"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062437"},{"key":"e_1_3_2_60_2","volume-title":"Plavix (clopidogrel bisulfate) [package insert].","year":"2009","unstructured":"Plavix (clopidogrel bisulfate) [package insert]. New York NY, and Bridgewater, NJ: Bristol-Myers Squibb Sanofi-aventis; 2009."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.06.034"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90648-9"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.090"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.02.023"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02119-1"},{"key":"e_1_3_2_66_2","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson JJ","year":"2004","unstructured":"Ferguson JJ, Califf RM, Antman EM, et al.. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45\u201354.","journal-title":"JAMA"},{"key":"e_1_3_2_67_2","unstructured":"Deleted in proof."},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06887-8"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.6.696"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044259"},{"key":"e_1_3_2_71_2","first-page":"977","article-title":"Comparison of medical and surgical treatment for unstable angina pectoris","volume":"316","author":"Luchi RJ","year":"1987","unstructured":"Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1987;316:977\u201384.","journal-title":"Results of a Veterans Administration Cooperative Study. N Engl J Med"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-7-199704010-00012"},{"key":"e_1_3_2_73_2","first-page":"III107","article-title":"The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions.","volume":"54","author":"Takaro T","year":"1976","unstructured":"Takaro T, Hultgren HN, Lipton MJ, et al.. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circulation. 1976;54:III107\u2013III117.","journal-title":"Circulation."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.08.048"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.812636"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000130846.46168.03"},{"key":"e_1_3_2_78_2","first-page":"841","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity","volume":"103","author":"Sofi F","year":"2010","unstructured":"Sofi F, Marcucci R, Gori AM, et al.. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103:841\u20138.","journal-title":"An updated meta-analysis. Thromb Haemost"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.013"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61845-0"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.11.048"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1232"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808227"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.056"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91161-4"},{"key":"e_1_3_2_87_2","unstructured":"US Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Available at: http:\/\/www.fda.gov\/cder\/drug\/early_comm\/clopidogrel_bisulfate.htm. Accessed April 6 2009."},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.01.003"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.090251"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.261"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","unstructured":"Sofi F Giusti B Marcucci R et al.. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. March 30 2010. doi:10.1038\/tpj.2010.21.","DOI":"10.1038\/tpj.2010.21"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp041"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.109.865907"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.851949"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp157"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909475"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.002"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.01.003"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.082001"},{"key":"e_1_3_2_101_2","unstructured":"Deleted in proof."},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"e_1_3_2_103_2","unstructured":"Deleted in proof."},{"key":"e_1_3_2_104_2","first-page":"A27","article-title":"Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry","volume":"53","author":"Ramirez JF","year":"2009","unstructured":"Ramirez JF, Selzer F, Chakaprani R. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol. 2009;53:A27\u2013A28. Abstract.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-12-0808"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008315310"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.740324"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007964"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015163"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402103"},{"key":"e_1_3_2_112_2","first-page":"1757","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban","volume":"354","author":"Heeschen C","year":"1999","unstructured":"Heeschen C, Hamm CW, Goldmann B, et al.. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. 1999;354:1757\u201362.","journal-title":"PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet"},{"key":"e_1_3_2_113_2","first-page":"319","article-title":"Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb\/IIIa receptors","volume":"341","author":"Lincoff AM","year":"1999","unstructured":"Lincoff AM, Califf RM, Moliterno DJ, et al.. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb\/IIIa receptors. Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Investigators. N Engl J Med. 1999;341:319\u201327.","journal-title":"Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Investigators. N Engl J Med"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4801.100029"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362401"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908263410901"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21359"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.026"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.12.1593"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1267"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00006-0"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90752-2"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90409-T"},{"key":"e_1_3_2_126_2","first-page":"989","article-title":"Mural thrombi in myocardial infarctions","volume":"74","author":"Keating EC","year":"1983","unstructured":"Keating EC, Gross SA, Schlamowitz RA, et al.. Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography. Am J Med. 1983;74:989\u201395.","journal-title":"Prospective evaluation by two-dimensional echocardiography. Am J Med"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(92)91069-D"},{"key":"e_1_3_2_128_2","first-page":"77","article-title":"Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization","volume":"56","author":"Reeder GS","year":"1981","unstructured":"Reeder GS, Lengyel M, Tajik AJ, et al.. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc. 1981;56:77\u201381.","journal-title":"Mayo Clin Proc"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.72.854.731"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.95.2_Supplement.140S"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021328"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.009"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5627.366"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.24.3108"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09409-6"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000024408.81821.32"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020496"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc0502.103329"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011258"},{"key":"e_1_3_2_140_2","first-page":"1177","article-title":"CARS trial: warfarin and thrombin generation","volume":"350","author":"Peverill RE","year":"1997","unstructured":"Peverill RE, Harper RW, Smolich JJ. CARS trial: warfarin and thrombin generation. Coumadin Aspirin Reinfarction Study. Lancet. 1997;350:1177\u20138.","journal-title":"Coumadin Aspirin Reinfarction Study. Lancet"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.08.050"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.913111"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810625"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.496"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.20.2626"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052521"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.014"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000160869.75810.98"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.8.933"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-9029"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.188629"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.041"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm498"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02844-8"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-7-200210010-00006"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-7-200210010-00007"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.5.1064"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411243312104"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02771-6"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.03.058"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.838169"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05551008"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3370"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.05.023"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.671644"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0b013e31815f3172"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.05.002"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2501080833"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.08.016"},{"key":"e_1_3_2_171_2","first-page":"133","article-title":"A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography","volume":"41","author":"Campbell DR","year":"1990","unstructured":"Campbell DR, Flemming BK, Mason WF, et al.. A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J. 1990;41:133\u20137.","journal-title":"Can Assoc Radiol J"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02758260"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02552154"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1177\/028418519303400118"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001887"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.6.1570"},{"key":"e_1_3_2_177_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.06.075"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.181.6.1811463"},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.687152"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2328"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.07.015"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.03.098"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054209"},{"key":"e_1_3_2_184_2","first-page":"2201","article-title":"Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"55","author":"Thiele H","year":"2010","unstructured":"Thiele H, Hildebrand L, Schirdewahn C, et al.. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol. 2010;55:2201\u20139.","journal-title":"The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.022"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.11.1377"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.109.865352"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.014"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.720946"},{"key":"e_1_3_2_190_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191099"},{"key":"e_1_3_2_191_2","unstructured":"American Heart Association. Get With the Guidelines: Available at: http:\/\/www.americanheart.org\/presenter.jhtml?identifier=1165. Accessed June 10 2009."},{"key":"e_1_3_2_192_2","unstructured":"National Cardiovascular Data Registry. Action Registry\u2014GWTG: Available at: http:\/\/www.ncdr.com\/webncdr\/ACTION\/Default.aspx. Accessed June 10 2009."},{"key":"e_1_3_2_193_2","unstructured":"QualityNet.com. Measure Comparison (Inpatient Hospital Quality Measures). Available at: http:\/\/www.qualitynet.org\/dcs\/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1138900297065. Accessed June 10 2009."},{"key":"e_1_3_2_194_2","unstructured":"The Joint Commission. Acute Myocardial Infarction Core Measure Set. Available at: http:\/\/www.jointcommission.org\/PerformanceMeasurement\/PerformanceMeasurement\/Acute+Myocardial+Infarction+Core+Measure+Set.htm. Accessed June 10 2009."},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68147-6"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.694141"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073102"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.699934"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708191"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.15.joc80026"},{"key":"e_1_3_2_201_2","unstructured":"Deleted in proof."},{"key":"e_1_3_2_202_2","unstructured":"Deleted in proof."},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61235-0"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.04.012"},{"key":"e_1_3_2_205_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.044"}],"updated-by":[{"DOI":"10.1161\/cir.0b013e318233a0f2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T00:00:00Z","timestamp":1316476800000}},{"DOI":"10.1161\/cir.0b013e31822319d0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000}}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIR.0b013e31820f2f3e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T23:23:12Z","timestamp":1715556192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0b013e31820f2f3e"}},"subtitle":["A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines"],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":204,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2011,5,10]]}},"alternative-id":["10.1161\/CIR.0b013e31820f2f3e"],"URL":"https:\/\/doi.org\/10.1161\/cir.0b013e31820f2f3e","relation":{"correction":[{"id-type":"doi","id":"10.1161\/CIR.0b013e318233a0f2","asserted-by":"object"},{"id-type":"doi","id":"10.1161\/CIR.0b013e31822319d0","asserted-by":"object"}]},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]},"assertion":[{"value":"2011-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}